Prolonged survival after intraperitoneal interleukin-2 immun
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
In the last decade, there has been an explosion in the interest and usage of immunotherapy for cancer beginning with the demonstration that checkpoint inhibitors could produce prolonged treatment-free remissions in patients with advanced melanoma. Immunotherapy with checkpoint inhibitors and as well as an oncolytic virus are now approved and available for the treatment of multiple advanced cancers. Although there is tremendous interest in using immunotherapy for ovarian cancer, success in this field seems limited at present. In addition most efforts emphasize systemic immunotherapy, with little attention to the intraperitoneal route for immunotherapeutic agents. The authors felt the report of a patient with recurrent ovarian cancer successfully treated with intra-peritoneal interleukin-2 14 years ago would be of interest...

http://bit.ly/2z73REz
Like
Comment
Share